Consegna Pharma is a Pittsburgh specialty pharmaceutical company that reformulates known, safe drugs into long-acting injectable medications with improved clinical and economic benefits. Its lead candidate, CP216, is a long-acting injectable naloxone designed to reverse an opioid overdose immediately and then release over 12 to 24 hours to prevent renarcotization. [1]
The company was founded in 2017 as a University of Pittsburgh spinout, with Larry Zana as founder, president, and CEO. In April 2022 it acquired Fathom Pharma, adding a pipeline of long-acting pain medicines. [2]